Equity capital markets

Contineum Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, April 5, 2024
Montgomery Street, Goldman Sachs, Vesey Street, Telephone, Inflammation, SAN, Sale, Attention, Security (finance), Prospectus, Morgan Stanley, Suite, Therapy, Varick Street, Equity capital markets, RBC Capital Markets

All of the shares are being offered by Contineum.

Key Points: 
  • All of the shares are being offered by Contineum.
  • The gross proceeds to Contineum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Contineum, are expected to be $110.0 million.
  • In addition, Contineum has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Morgan Stanley, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

Retrieved on: 
Tuesday, April 2, 2024
Vanderbilt Avenue, TD Securities, Exercise, Form, Telephone, Sale, Attention, Gritstone bio, Form S-3, Vaccine, Equity capital markets, Evercore, Security (finance)

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
  • The accompanying common warrants will be immediately exercisable for shares of common stock or pre-funded warrants in lieu thereof, and will expire on the twelve-month anniversary of the date of issuance.
  • All of the shares of common stock, accompanying common warrants and pre-funded warrants are being offered by Gritstone bio.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

Gritstone bio Announces Proposed Public Offering

Retrieved on: 
Monday, April 1, 2024
Vanderbilt Avenue, TD Securities, Form, Telephone, Sale, Attention, Gritstone bio, Form S-3, Vaccine, Equity capital markets, Evercore, Security (finance)

All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.

Key Points: 
  • All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • TD Cowen and Evercore ISI are acting as the joint book-running managers for the proposed offering.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

ATS Announces C$163 Million Secondary Offering of Common Shares

Retrieved on: 
Wednesday, March 27, 2024
ATS, System, Offering, Vesey Street, Partnership, Form, Telephone, Underwriting, Sale, News, Attention, Closing, TSX, Mason, Equity capital markets, Register, Prospectus, Security (finance)

The Offering is expected to close on or about April 3, 2024 (the “Closing”).

Key Points: 
  • The Offering is expected to close on or about April 3, 2024 (the “Closing”).
  • All of the shares in the Offering will be sold by the Selling Shareholder.
  • The Company will not receive any proceeds from the sale of the Shares by the Selling Shareholder.
  • The Selling Shareholder notes, “As a long-time investor in ATS, Mason remains committed to the Company as reflected by our significant ownership stake.

Marex Group plc Announces Filing of Registration Statement for Proposed Initial Public Offering

Retrieved on: 
Tuesday, March 26, 2024
Attention, Seventh Avenue, Madison Avenue, Goldman Sachs, 4th floor, Form, Keefe, Bruyette & Woods, Marex, Sale, Prospectus, Broadridge Financial Solutions, Jefferies, Equity capital markets, Jefferies Group, Barclays, Cryptocurrency

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.
  • The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Barclays, Goldman Sachs & Co. LLC, Jefferies, and Keefe, Bruyette & Woods, a Stifel Company, are acting as joint lead book-running managers for the proposed offering.
  • A registration statement relating to these securities has been filed with the SEC but has not yet become effective.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Retrieved on: 
Monday, March 25, 2024
Janus, SVB Securities, Montgomery Street, Mizuho Securities, 3rd Floor, Telephone, SAN, Research, Sale, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Annual report, OrbiMed, Equity capital markets, NK, State Street

Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about March 27, 2024, subject to customary closing conditions.
  • All securities in the offering are to be issued and sold by Nkarta.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus describing the terms of the offering.

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Retrieved on: 
Tuesday, March 19, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.

Key Points: 
  • The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.
  • The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million.
  • Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.

Madrigal Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Monday, March 18, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.
  • All of the shares in the proposed offering are to be sold by Madrigal.
  • Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Evercore ISI, Piper Sandler, UBS Investment Bank and Citizens JMP are acting as joint bookrunning managers of the proposed offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Xcel Brands, Inc. Announces Pricing of $2.42 Million Public Offering of Common Stock and Concurrent Private Placement

Retrieved on: 
Friday, March 15, 2024
Telephone, Sale, Acquisition, Attention, Security (finance), Prospectus, Suite, Marketing, Equity capital markets, Capital Group Companies

All of the shares of common stock are being sold at a public offering price of $0.65 per share, for gross proceeds of $2,134,874, before underwriting discounts and commissions and offering expenses, and included participation from members of Xcel’s management.

Key Points: 
  • All of the shares of common stock are being sold at a public offering price of $0.65 per share, for gross proceeds of $2,134,874, before underwriting discounts and commissions and offering expenses, and included participation from members of Xcel’s management.
  • The offering is expected to close on or about March 19, 2024.
  • The offering of securities will be made only by means of the prospectus and prospectus supplement that forms a part of the registration statement.
  • A preliminary prospectus supplement and accompanying prospectus relating to, and describing the terms of, the offering, will be filed with the SEC and will be available on the SEC's website at www.sec.gov .

Xcel Brands, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, March 14, 2024
Telephone, Sale, Acquisition, Attention, Security (finance), Prospectus, Suite, Xcel Energy, Marketing, Equity capital markets, Capital Group Companies

All of the shares of common stock (or common stock equivalents) are being offered by Xcel.

Key Points: 
  • All of the shares of common stock (or common stock equivalents) are being offered by Xcel.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for the offering.
  • The offering of securities will be made only by means of the prospectus and prospectus supplement that forms a part of the registration statement.